₹-6.20
(Market cap
₹1,635 Cr
Recently Viewed
Clear AllMarket cap
₹1,635 Cr
Revenue (TTM)
₹409 Cr
P/E Ratio
--
P/B Ratio
4.1
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹-89 Cr
ROE
-44.6 %
ROCE
-12.6 %
Industry P/E
31.42
EV/EBITDA
-404.2
Debt to Equity
2.4
Book Value
₹178.7
EPS
₹-42.1
Face value
10
Shares outstanding
22,282,238
CFO
₹347.02 Cr
EBITDA
₹594.07 Cr
Net Profit
₹141.52 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Astec Lifesciences
| 4.2 | 30.5 | 23.7 | -3.3 | -18.7 | -6.7 | 12.9 |
|
BSE Commodities
| 5.8 | 10.8 | 4.8 | 14.9 | 18.3 | 13.5 | 16.0 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Astec Lifesciences
| -27.8 | -7.3 | -37.5 | 22.2 | 11.2 | 195.2 | -13.9 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Commodities
| 12.5 | 8.1 | 17.5 | 1.2 | 61.5 | 26.1 | -4.6 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Astec Lifesciences
|
734.4 | 1,635.2 | 409.1 | -89.2 | -12.9 | -26.9 | -- | 4.1 |
| 4,739.2 | 21,313.3 | 5,620.6 | 670.4 | 13.4 | 22.4 | 31.8 | 6.6 | |
| 262.5 | 3,408.4 | 500.5 | 13.2 | 5.5 | 1.9 | 257.9 | 4.9 | |
| 1,441.2 | 2,391.9 | 1,240.4 | 132.3 | 13.1 | 12.2 | 18 | 1.9 | |
| 1,071.1 | 4,824.7 | 1,978.5 | 265.0 | 16.3 | 18 | 18.2 | 3.0 | |
| 706.9 | 2,056.6 | 2,072.7 | 140.8 | 9.5 | 12.4 | 14.5 | 1.7 | |
| 161.3 | 3,786.7 | 1,424.9 | -44.7 | -1.1 | -13.7 | -- | 5.5 | |
| 261.6 | 5,081.5 | 2,871.0 | 167.0 | 7.8 | 11.7 | 30.4 | 2.5 | |
| 1,111.1 | 10,012.2 | 5,031.2 | 565.9 | 9.9 | 21.9 | 17.7 | 3.5 | |
| 447.6 | 22,306.8 | 3,234.0 | 531.4 | 18.3 | 17.8 | 42 | 6.8 |
No Review & Analysis are available.
Astec LifeSciences Limited, together with its subsidiaries, manufactures and sells agrochemical active ingredients and pharmaceutical intermediates in India. The company provides triazole fungicides for use in field crops; foliar treatment for the... control of scab, powdery mildew, shot-hole, blossom blight, and rust; seed treatment for the control of seed and soil-borne diseases in cotton and maize, as well as grains, such as barley, rice, and wheat; post-harvest drench; and food additive and wood preservative. It also provides herbicides, insecticides, and specialty chemical products. The company also exports its products. The company was incorporated in 1994 and is based in Mumbai, India. Astec LifeSciences Limited is a subsidiary of Godrej Agrovet Limited. Read more
Incorporated
1994
Chairman
Vishal Sharma
Managing Director
Burjis Godrej
Group
Godrej
Headquarters
Mumbai, Maharashtra
Website
Looking for more details about Astec Lifesciences Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsClarification To BSE Regarding Price Movement
20-Apr-2026Clarification sought from Astec Lifesciences Ltd
17-Apr-2026No News & Announcements are available.
The share price of Astec Lifesciences Ltd is ₹734.40 (NSE) and ₹733.85 (BSE) as of 23-Apr-2026 IST. Astec Lifesciences Ltd has given a return of -18.75% in the last 3 years.
Since, TTM earnings of Astec Lifesciences Ltd is negative, P/E ratio is not available.
The P/B ratio of Astec Lifesciences Ltd is 4.11 times as on 23-Apr-2026, a 30 premium to its peers’ median range of 3.16 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
5.64
|
|
2024
|
0.00
|
5.65
|
|
2023
|
106.02
|
6.47
|
|
2022
|
38.22
|
8.67
|
|
2021
|
30.12
|
6.35
|
The 52-week high and low of Astec Lifesciences Ltd are Rs 990.82 and Rs 513.40 as of 23-Apr-2026.
Astec Lifesciences Ltd has a market capitalisation of ₹ 1,635 Cr as on 23-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Astec Lifesciences Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.